![]() |
Sydney, Dec 7, 2011 (ABN Newswire) - Great Wall Motors (
HKG:2333) has received EU Whole Vehicle Type Approval for its Voleex C30 and Voleex C20R. Voleex C30, Great Wall's first three-box car, is one of the Top 10 Compact Family Cars in terms of sales volume in China in 2011, and has already been sold to more than 50 countries and regions. Voleex C20R, a cross vehicle type featuring sports characteristics and multiple functions, provides superior comfort and driving excitement.
Chevalier International Holdings Limited (
HKG:0025) has entered into a letter of intent in relation to possible acquisitions of certain hot spring hotels in Japan. Chevalier International is principally engaged in construction and engineering, insurance and investment, property development and investment, food and beverages, and computer and information communication technology. The acquisition, if completed, will help Chevalier diversify its income stream and gain from the development of the Japanese tourism industry.
Daiichi Sankyo Co., Ltd (
TYO:4568) advises that its subsidiary Ranbaxy Laboratories Ltd. (
BOM:500359), India's largest pharmaceutical company, has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin, a cholesterol-reducing medicine, in the US market. Atorvastatin will provide a safe, effective, affordable and accessible alternative to Pfizer's (
NYSE:PFE) cholesterol-lowering medication Lipitor, which generated total annual sales of US$7.89 billion in the US through September 2011.
HKG:2333) has received EU Whole Vehicle Type Approval for its Voleex C30 and Voleex C20R. Voleex C30, Great Wall's first three-box car, is one of the Top 10 Compact Family Cars in terms of sales volume in China in 2011, and has already been sold to more than 50 countries and regions. Voleex C20R, a cross vehicle type featuring sports characteristics and multiple functions, provides superior comfort and driving excitement. Chevalier International Holdings Limited (
HKG:0025) has entered into a letter of intent in relation to possible acquisitions of certain hot spring hotels in Japan. Chevalier International is principally engaged in construction and engineering, insurance and investment, property development and investment, food and beverages, and computer and information communication technology. The acquisition, if completed, will help Chevalier diversify its income stream and gain from the development of the Japanese tourism industry.Daiichi Sankyo Co., Ltd (
TYO:4568) advises that its subsidiary Ranbaxy Laboratories Ltd. (
BOM:500359), India's largest pharmaceutical company, has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin, a cholesterol-reducing medicine, in the US market. Atorvastatin will provide a safe, effective, affordable and accessible alternative to Pfizer's (
NYSE:PFE) cholesterol-lowering medication Lipitor, which generated total annual sales of US$7.89 billion in the US through September 2011.| Tweet |
|
||
|
![]() |
Related Companies |
>>> >>> >>> >>> >>> |
![]() |
Related Industry Topics: |
Auto Manufacturing | Consumers General | Financial General | Health & Pharm General | Auto General | Chem General | Building & Construction | Australian Economy | Market Reports | |
![]() |
This Page Viewed: (Last 7 Days: 240) (Last 30 Days: 1150) (Since Published: 10890) |
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
| Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
| Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
| Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
| Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
![]() |
Daiichi Sankyo Company, Limited | ||
|
|||
Companies in the News
Mobile Video TV
|
||
|
||








